February 17, 2017
Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
February 15, 2017
Theravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017
February 13, 2017
Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: